-
Dr. Liang Han: Phase III MATTERHORN Study Shows Significant Improvement in pCR for Neoadjuvant Treatment of Gastric Cancer with Pembrolizumab
Editor’s Note:This 2023 ESMO Annual Meeting, in the field of gastric cancer, the global Phase III MATTERHORN study of the anti-PD-L1 antibody pembrolizumab in combination with the FLOT regimen for…
-
ESMO Exclusive Interview | Professor Huiyan Luo : Significant Efficacy of the Combination of Anti-PD-L1/TGF-βRII Dual-Target Antibody SHR-1701 with Bevacizumab in the Treatment of Advanced Solid Tumors
Editor’s Note: The 2023 European Society for Medical Oncology (ESMO) Annual Meeting took place from October 20th to 24th in Madrid, Spain. The Oncology Insights Reporting Team delved deep into…
-
ESMO 2023 | Professor Ning Liao: The Extension of the T-DXd Anti-HER2 Landscape in DESTINY-PanTumor01
Editor’s Note: Anti-HER2 therapy has traditionally been implemented based on HER2 expression detected through immunohistochemistry. In clinical practice, a small subset of patients with HER2-negative expression may have HER2 gene…
-
ESMO China Voice | Professor Shichun Lu : Targeted Immunotherapy Offers Hope for Curative Resection and Long-Term Survival in Unresectable Liver Cancer
Due to the insidious nature of liver cancer, most patients are diagnosed in the advanced stages, losing the opportunity for curative surgery and facing a poor prognosis. In recent years,…
-
ESMO Big Shot Face to Face | Professor Shun Lu : Roxadustat Leads the Way in CIA Management
The 2023 European Society for Medical Oncology (ESMO) Congress opened grandly in Madrid, Spain on October 20. Top global oncology experts gathered to discuss and share the latest international advances…
-
ESMO 2023: Prof. Feng Wang – “Combination Targeted Immunotherapy” Opens a New Era of Precision Treatment for Esophageal and Gastric Cancer in China
Editor’s note: The 2023 ESMO Annual Meeting took place in Madrid, Spain, from October 20th to 24th. As a prestigious annual event in the field of oncology, it unveils cutting-edge…
-
ESMO Hot Topics Update: New Developments in Precision Diagnosis and Treatment with Talazoparib
At this year’s recently concluded ESMO conference, new developments related to the PARP inhibitor talazoparib in precision diagnosis and treatment were announced. Precision diagnosis has become a leading trend in the field of prostate cancer, and biomarker research is receiving increasing attention. In this context, this publication invited Professor Guiming Zhang from Qingdao University Affiliated…
-
ESMO Exclusive Interview | Professor HuiyanLuo : Significant Efficacy of the Combination of Anti-PD-L1/TGF-βRII Dual-Target Antibody SHR-1701 with Bevacizumab in the Treatment of Advanced Solid Tumors
The 2023 European Society for Medical Oncology (ESMO) Annual Meeting took place from October 20th to 24th in Madrid, Spain. The Oncology Insights Reporting Team delved deep into the front lines to witness international advancements and to witness the progress of China’s anti-tumor efforts on the global stage. Professor Huiyan Luo from Sun Yat-sen University…
Connecting Medical Expertise through Media